CD95 in cancer: Tool or target?

Trends in Molecular Medicine

Volumn 19, Issue 6, 2013, Pages 329-335

  Martin Villalba, Ana ^a   Llorens Bobadilla, Enric ^a   Wollny, Damian ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cancer therapy; CD95; Clinical studies; FAS; Tumorigenesis

Indexed keywords

CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCASPASE 8; PROTEIN KINASE SYK; PROTEIN SH2; UROKINASE;

APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CHROMOSOME 19; CLINICAL TRIAL (TOPIC); ENZYME ACTIVATION; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; NEOPLASM; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE GROWTH; TRANSACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; GENETICS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84878602168     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.03.002     Document Type: Review

References (56)

1. Trauth B.C., et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
2. Itoh N., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
3. Oehm A., et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992, 267:10709-10715.
4. Scott F.L., et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009, 457:1019-1022.
5. Schleich K., et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol. Cell 2012, 47:306-319.
6. Dickens L.S., et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 2012, 47:291-305.
7. Kischkel F., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 14:5579-5588.
8. Oberst A., et al. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
9. Kaiser W.J., et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011, 471:368-372.
10. Zhang H., et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011, 471:373-376.
11. Barnhart B.C., et al. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004, 23:3175-3185.
12. Chen L., et al. CD95 promotes tumour growth. Nature 2010, 465:492-496.
13. Cursi S., et al. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006, 25:1895-1905.
14. Barbero S., et al. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res. 2009, 69:3755-3763.
15. Finlay D., et al. Critical role for caspase-8 in epidermal growth factor signaling. Cancer Res. 2009, 69:5023-5029.
16. Senft J., et al. Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res. 2007, 67:11505-11509.
17. Kleber S., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
18. Steller E.J.A., et al. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep. 2011, 12:931-937.
19. Letellier E., et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010, 32:240-252.
20. Hoogwater F.J.H., et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010, 138:2357-2367.
21. Reinehr R., et al. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 2008, 134:1494-1506.
22. Reinehr R., et al. The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95. J. Biol. Chem. 2004, 279:23977-23987.
23. Bivona T.G., et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
24. Stommel J.M., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
25. Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
26. Ivaska J., Heino J. Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu. Rev. Cell Dev. Biol. 2011, 27:291-320.
27. Watanabe-Fukunaga R., et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
28. Roths J.B., et al. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 1984, 159:1-20.
29. Matsuzawa A., et al. A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse. J. Exp. Med. 1990, 171:519-531.
30. Lynch D.H., et al. The mouse Fas-ligand gene is mutated in g/cl mice and is part of a TNF family gene cluster. Immunity 1994, 1:131-136.
31. Adachi M., et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 1995, 11:294-300.
32. Karray S., et al. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J. Immunol. 2004, 172:2118-2125.
33. Hao Z., et al. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J. Exp. Med. 2004, 199:1355-1365.
34. Akiyama K., et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012, 10:544-555.
35. Chen J-J., et al. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998, 282:1714-1717.
36. Kang S.M., et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 1997, 3:738-743.
37. Demjen D., et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat. Med. 2004, 10:389-395.
38. Newell M.K., Desbarats J. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 2000, 6:920-923.
39. Badorff C., et al. Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 2002, 109:373-381.
40. Corsini N.S., et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009, 5:178-190.
41. O'Reilly L.A., et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
42. James J.R., Vale R.D. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 2012, 487:64-69.
43. Lee J-K., et al. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003, 8:151-160.
44. Peter M.E., et al. The CD95 receptor: apoptosis revisited. Cell 2007, 129:447-450.
45. Li H., et al. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology 2009, 137:934-944.
46. Nijkamp M.W., et al. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J. Hepatol. 2010, 53:1069-1077.
47. Kataoka T., et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol. 2000, 10:640-648.
48. Nakamoto Y., et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-Fas ligand antibody therapy. J. Exp. Med. 2002, 196:1105-1111.
49. Ogasawara J., et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
50. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
51. Xu Y., et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 2003, 171:562-568.
52. Holler N., et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 2003, 23:1428-1440.
53. Eisele G., et al. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011, 13:155-164.
54. Verbrugge I., et al. Combining radiotherapy with APO010 in cancer treatment. Clin. Cancer Res. 2009, 15:2031-2038.
55. Tuettenberg J., et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int. Immunopharmacol. 2012, 13:93-100.
56. Bendszus M., et al. A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. J. Clin. Oncol. (Meeting Abstracts) 2012, 30(Suppl. 15). Abstract 2034.